We updated the design of this site on December 18, 2017. Learn more.
ClinicalTrials.gov Menu

Effect of Januvia on Ghrelin and Other Gut Hormones in Patients With Diabetes

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT00790348
Recruitment Status : Unknown
Verified October 2008 by Wayne State University.
Recruitment status was:  Recruiting
First Posted : November 13, 2008
Last Update Posted : November 13, 2008
Information provided by:
Wayne State University

Brief Summary:
The purpose of this study is to see the effect of Januvia on Ghrelin levels in patients with diabetes.

Condition or disease
Type 2 Diabetes

Study Type : Observational
Estimated Enrollment : 45 participants
Time Perspective: Cross-Sectional
Official Title: Effect of Januvia on Ghrelin and Other Gut Hormones in Patients With Diabetes
Study Start Date : July 2008
Estimated Primary Completion Date : July 2009

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Hormones
U.S. FDA Resources

Patients who on Januvia
Patients on Janumet (Combination of Januvia and Metformin)
Patients on Metformin

Biospecimen Retention:   Samples Without DNA
Serum of patients will be kept for future studies

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Ages Eligible for Study:   18 Years to 80 Years   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Sampling Method:   Probability Sample
Study Population
Patients with type 2 diabetes on oral agent that require Metformin or Januvia only

Inclusion Criteria:

  • Patients with Type 2 diabetes

Exclusion Criteria:

  • Renal failure
  • Pregnancy

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00790348

United States, Michigan
Wayne State University Recruiting
Detroit, Michigan, United States, 48201
Contact: Berhane Seyoum, MD    313-745-4008    bseyoum@med.wayne.edu   
Principal Investigator: Berhane Seyoum, MD, MPH         
Sponsors and Collaborators
Wayne State University

Responsible Party: Berhane Seyoum, Wayne State University
ClinicalTrials.gov Identifier: NCT00790348     History of Changes
Other Study ID Numbers: 0709005250
First Posted: November 13, 2008    Key Record Dates
Last Update Posted: November 13, 2008
Last Verified: October 2008

Additional relevant MeSH terms:
Diabetes Mellitus
Glucose Metabolism Disorders
Metabolic Diseases
Endocrine System Diseases
Sitagliptin Phosphate
Hormones, Hormone Substitutes, and Hormone Antagonists
Physiological Effects of Drugs
Hypoglycemic Agents
Dipeptidyl-Peptidase IV Inhibitors
Protease Inhibitors
Enzyme Inhibitors
Molecular Mechanisms of Pharmacological Action